Article Text

Download PDFPDF

Response to: ‘Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis’ by Chevreau et al
  1. Maria Karolina Jonsson1,2,
  2. Nina Paulshus Sundlisæter2,
  3. Hilde Haugedal Nordal1,3,
  4. Hilde Berner Hammer2,
  5. Anna-Birgitte Aga2,
  6. Désirée van der Heijde2,4,
  7. Tore Kristian Kvien2,
  8. Bjørg-Tilde Svanes Fevang1,3,
  9. Siri Lillegraven2,
  10. Espen Andre Haavardsholm2,5
  1. 1 Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease, Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
  2. 2 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  3. 3 Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
  4. 4 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  5. 5 Institute of Health and Society, University of Oslo, Oslo, Norway
  1. Correspondence to Dr Maria Karolina Jonsson, Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease, Department of Rheumatology, Haukeland University Hospital, Bergen 5021, Norway; jonssonmk{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We appreciate the additional data regarding calprotectin and radiographic progression provided by Chevreau et al 1 as an eLetter addressing our published research paper.2 It is important to explore new biomarkers in different cohorts of patients with early and established rheumatoid arthritis (RA). Calprotectin levels have previously been shown to be associated with joint damage in established RA.3 4 Hammer et al 5 have shown that calprotectin was an independent predictor of radiographic joint damage after 10 years of follow-up. Chevreau et al present data on baseline calprotectin as a predictor of rapid radiographic progression (defined as an increase of ≥5 van der Heijde Sharp score units/year) in a large cohort of patients with early RA, and did not find calprotectin to be associated with structural damage when baseline erosions were considered.1

In order to address the issues raised by Chevreau et al 1 we performed additional statistical analyses. When introducing baseline van der Heijde modified Sharp erosion score in the multivariate model (including erythrocyte sedimentation rate, C reactive protein, age, gender, Clinical Disease Activity Index and rheumatoid factor (RF)), baseline erosion score was a significant predictor of radiographic progression (OR 1.14, 95% CI 1.02 to 1.28; table 1). Importantly, calprotectin in the highest quartile remained a significant independent predictor of radiographic damage in the multivariate model (OR 3.52, 95% CI 1.15 to 10.72; table 1). RF was a stronger predictor than anticitrullinated peptide antibody (ACPA) in univariate models; thus, we chose to include RF in our initial model.2 When assessing the multivariate model including ACPA instead of RF, both calprotectin and baseline erosions remained significant independent predictors of radiographic progression, while ACPA was not a significant predictor (OR 1.27, 95% CI 0.52 to 3.08, p=0.60).

Table 1

Predictors of radiographic progression ≥1 unit/year from 0 to 24 months (n=215)

Comparison between cohorts should be done with caution, and the Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen (ARCTIC)6 and Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohorts7 are different. Serologically, 44% vs 39% of patients were positive for RF-IgM and ACPA in the ESPOIR cohort compared with 71% and 82% in the ARCTIC cohort. Treatment strategies were different in the two cohorts; in ESPOIR there were no protocol-based treatment strategies, as opposed to ARCTIC with a structured, aggressive tight control algorithm aiming for remission. In the ARCTIC cohort, 41% of disease-modifying antirheumatic drug-naïve patients with early RA progressed radiographically during the 2 years of follow-up, with radiographic progression defined as ≥1 unit/year from 0 to 24 months.2 However, rapid radiographic progression was rare, occurring in only 11 out of the 230 patients included in the full analyses set.

In modern RA care, patients are identified at an early stage and often before radiographic damage is evident. In such a setting, our results indicate that calprotectin may be an independent predictor of radiographic damage, but the role of calprotectin needs to be further investigated in different cohorts before being fully implemented in routine care.


We would like to thank Inge Dale at CalproLab, Marianne Eidsheim at Broegelmann Research Laboratory, Ellen Moholt and Camilla Fongen at Diakonhjemmet Hospital, and the ARCTIC study group.



  • Handling editor Josef S Smolen

  • Competing interests MKJ reports grants from Norwegian Extra Foundation for Health and Rehabilitation and non-financial support from Calpro AS during the conduct of the study. TKK has received fees for speaking and/or consulting from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, and received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB. EAH has received research funding from Pfizer, UCB, Roche, MSD and AbbVie, honorariums as a speaker from Pfizer, UCB, Roche and AbbVie, and honorariums for development of educational material from Pfizer, and has sat on advisory boards for Pfizer.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles